Marshall Wace’s Relay Therapeutics RLAY Stock Holding History

Marshall Wace’s Portfolio RLAY Stock Details RLAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$9.37M	Buy	+941,825	New	+$8.43M	0.01%	1009
2025 Q3	–	Sell	-51,698	Closed	-$179K	–	3329
2025 Q2	$179K	Buy	+51,698	New	+$154K	﹤0.01%	2476
2025 Q1	–	Sell	-27,768	Closed	-$114K	–	3023
2024 Q4	$114K	Sell	27,768 -1,377,946	-98%	-$7.5M	﹤0.01%	2429
2024 Q3	$9.95M	Buy	1,405,714 +1,129,012	+408%	+$8.43M	0.01%	766
2024 Q2	$1.8M	Buy	+276,702	New	+$1.89M	﹤0.01%	1426
2022 Q1	–	Sell	-2,499	Closed	-$77K	–	3914
2021 Q4	$77K	Sell	2,499 -17,231	-87%	-$545K	﹤0.01%	3452
2021 Q3	$622K	Sell	19,730 -69,101	-78%	-$2.33M	﹤0.01%	2287
2021 Q2	$3.25M	Buy	88,831 +78,729	+779%	+$2.59M	0.01%	1093
2021 Q1	$349K	Buy	+10,102	New	+$438K	﹤0.01%	2076

Other funds holding RLAY

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Marshall Wace's RLAY Position: Q1 2026 in Review

Marshall Wace opened a new position in Relay Therapeutics (RLAY) in Q1 2026: 941,825 shares worth $9.37M. The stake represents 0.01% of the portfolio and ranks #1009 among its holdings. This is a return to the name: Marshall Wace previously reported a position in RLAY as recently as Q2 2025.

Marshall Wace first reported a position in RLAY in Q1 2021 and has held it in 9 quarters since. The position peaked at $9.95M in Q3 2024. 242 funds tracked by Wall St. Rank hold RLAY as of Q1 2026.

Marshall Wace held 941,825 shares of Relay Therapeutics worth $9.37M as of Q1 2026.
Relay Therapeutics was a new Marshall Wace position in Q1 2026.
Relay Therapeutics made up 0.01% of Marshall Wace's portfolio in Q1 2026, its #1009 holding.
Marshall Wace first reported a position in Relay Therapeutics in Q1 2021 and has held it in 9 quarters since.
Marshall Wace's Relay Therapeutics position peaked at $9.95M in Q3 2024.
242 funds tracked by Wall St. Rank held Relay Therapeutics as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.